Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBIT (2016 - 2025)

Catalyst Pharmaceuticals' EBIT history spans 16 years, with the latest figure at -$136.4 million for Q4 2025.

  • For Q4 2025, EBIT fell 317.04% year-over-year to -$136.4 million; the TTM value through Dec 2025 reached $59.5 million, down 69.49%, while the annual FY2025 figure was $59.5 million, 69.49% down from the prior year.
  • EBIT reached -$136.4 million in Q4 2025 per CPRX's latest filing, down from $66.3 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $66.3 million in Q2 2025 to a low of -$136.4 million in Q4 2025.
  • Average EBIT over 5 years is $24.8 million, with a median of $29.7 million recorded in 2022.
  • Peak YoY movement for EBIT: surged 236.9% in 2024, then crashed 317.04% in 2025.
  • A 5-year view of EBIT shows it stood at $12.7 million in 2021, then soared by 141.73% to $30.8 million in 2022, then skyrocketed by 35.36% to $41.7 million in 2023, then surged by 50.73% to $62.8 million in 2024, then plummeted by 317.04% to -$136.4 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's EBIT are -$136.4 million (Q4 2025), $66.3 million (Q3 2025), and $66.3 million (Q2 2025).